T cells can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19.

Afive-year community outreach and engagement effort more than doubled the percentage of participants, improving access and treatment for a group with historically low representation in cancer research.

With the disruption of cancer care since the pandemic began in March 2020, recent reports are starting to show that the interruption—while still significant—may not be as detrimental as experts originally feared.

Penn Medicine researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation.

The Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center received the award for his work in developing chimeric antigen receptor (CAR) T cell therapy.

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments.

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study.

While individuals who are vaccinated feel relief that they’re better protected, the rollout of vaccines to anyone in their community is still good news.

Findings represent the longest follow-up data to date for a personalized cellular therapy approved by the FDA for the treatment of aggressive lymphomas.

The Richard W. Vague professor in Immunotherapy in the department of Pathology and Laboratory Medicine has been recognized in the “future” category for his contributions to molecular medicine.